Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours
Status:
Completed
Trial end date:
2019-08-22
Target enrollment:
Participant gender:
Summary
This is an open-label, multi-centre, Phase Ib study of AZD1775 designed to assess the safety,
tolerability, pharmacokinetics, and anti-tumour activity of AZD1775 monotherapy in patients
with advanced solid tumours.